Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

Bernard H. Bochner, MD, FACS
Published: Friday, Jan 10, 2020



Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center (MSKCC), discusses the potential standardization of molecular profiling in bladder cancer.
 
The utility of molecular profiling is in its infancy, says Bochner. However, testing has the potential to impact treatment options for many patients.
 
For example, molecular profiling may provide insight on potentially targetable mutations in patients who do not respond to standard treatment like intravesical therapy or those with metastatic disease who progress through first- and second-line therapy.
 
At MSKCC, molecular profiling is commonly used to obtain data regarding how a patient’s genomicmakeup can enhance treatment, explains Bochner. Though standardization is not ready for primetime, molecular profiling may become commonplace in the future.
SELECTED
LANGUAGE


Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center (MSKCC), discusses the potential standardization of molecular profiling in bladder cancer.
 
The utility of molecular profiling is in its infancy, says Bochner. However, testing has the potential to impact treatment options for many patients.
 
For example, molecular profiling may provide insight on potentially targetable mutations in patients who do not respond to standard treatment like intravesical therapy or those with metastatic disease who progress through first- and second-line therapy.
 
At MSKCC, molecular profiling is commonly used to obtain data regarding how a patient’s genomicmakeup can enhance treatment, explains Bochner. Though standardization is not ready for primetime, molecular profiling may become commonplace in the future.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x